Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP Gen Counsel, Legal & Comp | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,759 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-10 · Exercise / conversion · Acquired 590 · Balance 9,044 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2026-09-10 · Tax withholding · Disposed 285 · Balance 8,759 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 13,405 |
Reported balance
After 2026-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-10 · Exercise / conversion · Disposed 590 · Balance 13,405 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · derivative · entry 3 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,405 Underlying: Common Stock · 590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 285 | $144.81 | $41,270.85 |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · nonDerivative · entry 2 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,759 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 6,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · derivative · entry 3 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,995 Underlying: Common Stock · 6,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,908 | $133.06 | $386,938.48 |
DisclosureSEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · nonDerivative · entry 2 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,454 Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · derivative · entry 3 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,997 Underlying: Common Stock · 589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 283 | $121.48 | $34,378.84 |
DisclosureSEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · nonDerivative · entry 2 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 18,885 | $0.00 Strike: $148.56 | $0.00 |
DisclosureSEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 5 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,885 Underlying: Common Stock · 18,885 shares Expires 2036-03-10 F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 5,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 4 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,586 Underlying: Common Stock · 5,050 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 3 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,536 Underlying: Common Stock · 1,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 606 | $148.56 | $90,027.36 |
DisclosureSEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · nonDerivative · entry 2 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,054 Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 470 | $0.00 | $0.00 |
DisclosureSEC source: 0002110603-26-000004 · wk-form4_1772488110.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,414 F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.